Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 2
2006 1
2008 1
2009 2
2010 2
2011 1
2012 2
2013 3
2014 4
2015 3
2016 2
2017 6
2018 2
2019 3
2020 4
2021 6
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.
Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP. Nelson ER, et al. Among authors: wardell se. Science. 2013 Nov 29;342(6162):1094-8. doi: 10.1126/science.1241908. Science. 2013. PMID: 24288332 Free PMC article.
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
Chakraborty B, Byemerwa J, Shepherd J, Haines CN, Baldi R, Gong W, Liu W, Mukherjee D, Artham S, Lim F, Bae Y, Brueckner O, Tavares K, Wardell SE, Hanks BA, Perou CM, Chang CY, McDonnell DP. Chakraborty B, et al. Among authors: wardell se. J Clin Invest. 2021 Dec 1;131(23):e151347. doi: 10.1172/JCI151347. J Clin Invest. 2021. PMID: 34637400 Free PMC article.
Next-Generation Endocrine Therapies for Breast Cancer.
McDonnell DP, Wardell SE, Chang CY, Norris JD. McDonnell DP, et al. Among authors: wardell se. J Clin Oncol. 2021 Apr 20;39(12):1383-1388. doi: 10.1200/JCO.20.03565. Epub 2021 Mar 11. J Clin Oncol. 2021. PMID: 33705209 Free PMC article. No abstract available.
Targeting mutant estrogen receptors.
Wardell SE, Norris JD, McDonnell DP. Wardell SE, et al. Elife. 2019 Jan 16;8:e44181. doi: 10.7554/eLife.44181. Elife. 2019. PMID: 30648967 Free PMC article.
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP. Wardell SE, et al. Breast Cancer Res Treat. 2020 Feb;179(3):769. doi: 10.1007/s10549-019-05498-0. Breast Cancer Res Treat. 2020. PMID: 31734822 Free PMC article.
Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.
Lowder LL, Powell M, Miller SE, Kishton RJ, Kelly CB, Cribb CB, Mastro-Kishton K, Chelvanambi M, Do PT, Govindapur RR, Wardell SE, McDonnell DP, Bartolotti LJ, Akkaraju GR, Frampton AR, Varadarajan S. Lowder LL, et al. Among authors: wardell se. J Med Chem. 2021 Sep 9;64(17):12651-12669. doi: 10.1021/acs.jmedchem.1c00615. Epub 2021 Aug 20. J Med Chem. 2021. PMID: 34415160
Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.
Joh DY, Heggestad JT, Zhang S, Anderson GR, Bhattacharyya J, Wardell SE, Wall SA, Cheng AB, Albarghouthi F, Liu J, Oshima S, Hucknall AM, Hyslop T, Hall AHS, Wood KC, Shelley Hwang E, Strickland KC, Wei Q, Chilkoti A. Joh DY, et al. Among authors: wardell se. NPJ Breast Cancer. 2021 Sep 17;7(1):126. doi: 10.1038/s41523-021-00335-4. NPJ Breast Cancer. 2021. PMID: 34535683 Free PMC article. No abstract available.
42 results